Market capitalization | $11.01m |
Enterprise Value | $12.50m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 12.89 |
P/S ratio (TTM) P/S ratio | 11.35 |
P/B ratio (TTM) P/B ratio | 26.09 |
Revenue growth (TTM) Revenue growth | 0.87% |
Revenue (TTM) Revenue | $970.00k |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast PetVivo Holdings Inc:
1 Analyst has issued a forecast PetVivo Holdings Inc:
Sep '24 |
+/-
%
|
||
Revenue | 0.97 0.97 |
1%
1%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -9.05 -9.05 |
13%
13%
|
EBIT (Operating Income) EBIT | -9.18 -9.18 |
12%
12%
|
Net Profit | -8.62 -8.62 |
23%
23%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company. It is engaged in the business of translating or adapting human biotech and medical technology into products for commercialization in the veterinary market to treat companion animals such as dogs, horses, cats, and other animals suffering from osteoarthritis and other afflictions. The firm's lead product includes Kush, is an intra-articular injection comprised of patented, gel-like biomaterials that is being commercialized for companion animal osteoarthritis. The company was founded by John Lai and John F. Dolan on March 31, 2009 and is headquartered in Minneapolis, MN.
Head office | United States |
CEO | John Lai |
Employees | 20 |
Founded | 2009 |
Website | www.petvivo.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.